Effective Systolic Blood Pressure Reduction with Olmesartan Medoxomil/Amlodipine Combination TherapyPost Hoc Analysis of Data from a Randomized, Double-Blind, Parallel-Group, Multicentre Study

被引：0
|
作者：
Jean-Jacques Mourad
Sylvain Le Jeune
机构：
[1] Avicenne Hospital—Hypertension Unit and University Paris XIII,Assistance Publique
来源：
Clinical Drug Investigation | 2009年 / 29卷
关键词：
Systolic Blood Pressure; Amlodipine; HCTZ; Olmesartan; Olmesartan Medoxomil;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Background and objective: Systolic blood pressure (SBP) strongly predicts cardiovascular risk and is an important factor to evaluate in studies of anti-hypertensive treatments. A recent randomized controlled study has shown that the angiotensin II type 1 receptor antagonist (angiotensin receptor blocker [ARB]) olmesartan medoxomil (hereafter olmesartan) combined with the calcium channel antagonist (calcium channel blocker) amlodipine can control SBP in a majority of patients with moderate-to-severe hypertension. The aim of this report is to present results from a post hoc analysis of this study to further evaluate the effects of this combination on SBP.
引用
收藏
页码：419 / 425
页数：6
相关论文
共 50 条
12345